NTRK1 and metastatic neoplasm: In contrast, in a case report by Hempel et al., a patient with ESCA with NTRK1 gene amplification experienced shrinkage of primary and metastatic tumors within 6 weeks after treatment with the NTRK inhibitor larotrectinib, accompanied by a decrease in tumor markers (Hempel et al., 2020).